Literature DB >> 26808342

Cancer statistics in China, 2015.

Wanqing Chen1, Rongshou Zheng2, Peter D Baade3, Siwei Zhang4, Hongmei Zeng4, Freddie Bray5, Ahmedin Jemal6, Xue Qin Yu7,8, Jie He9.   

Abstract

With increasing incidence and mortality, cancer is the leading cause of death in China and is a major public health problem. Because of China's massive population (1.37 billion), previous national incidence and mortality estimates have been limited to small samples of the population using data from the 1990s or based on a specific year. With high-quality data from an additional number of population-based registries now available through the National Central Cancer Registry of China, the authors analyzed data from 72 local, population-based cancer registries (2009-2011), representing 6.5% of the population, to estimate the number of new cases and cancer deaths for 2015. Data from 22 registries were used for trend analyses (2000-2011). The results indicated that an estimated 4292,000 new cancer cases and 2814,000 cancer deaths would occur in China in 2015, with lung cancer being the most common incident cancer and the leading cause of cancer death. Stomach, esophageal, and liver cancers were also commonly diagnosed and were identified as leading causes of cancer death. Residents of rural areas had significantly higher age-standardized (Segi population) incidence and mortality rates for all cancers combined than urban residents (213.6 per 100,000 vs 191.5 per 100,000 for incidence; 149.0 per 100,000 vs 109.5 per 100,000 for mortality, respectively). For all cancers combined, the incidence rates were stable during 2000 through 2011 for males (+0.2% per year; P = .1), whereas they increased significantly (+2.2% per year; P < .05) among females. In contrast, the mortality rates since 2006 have decreased significantly for both males (-1.4% per year; P < .05) and females (-1.1% per year; P < .05). Many of the estimated cancer cases and deaths can be prevented through reducing the prevalence of risk factors, while increasing the effectiveness of clinical care delivery, particularly for those living in rural areas and in disadvantaged populations.
© 2016 American Cancer Society.

Entities:  

Keywords:  China; cancer; health disparities; incidence; mortality; survival; trends

Mesh:

Year:  2016        PMID: 26808342     DOI: 10.3322/caac.21338

Source DB:  PubMed          Journal:  CA Cancer J Clin        ISSN: 0007-9235            Impact factor:   508.702


  2000 in total

1.  [Expression of secreted frizzled-related protein 4 in DNA mismatch repair-deficient and mismatch repair-proficient colorectal cancers].

Authors:  Kexu Chen; Hanlin Liang; Jiewen Peng; Yanfang Zheng
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2018-11-30

2.  FBXO4 inhibits lung cancer cell survival by targeting Mcl-1 for degradation.

Authors:  C Feng; F Yang; J Wang
Journal:  Cancer Gene Ther       Date:  2017-08-04       Impact factor: 5.987

3.  Nedaplatin and paclitaxel compared with carboplatin and paclitaxel for patients with platinum-sensitive recurrent ovarian cancer.

Authors:  Li Ge; Ning Li; Guang-Wen Yuan; Yang-Chun Sun; Ling-Ying Wu
Journal:  Am J Cancer Res       Date:  2018-06-01       Impact factor: 6.166

4.  SNRPA enhances tumour cell growth in gastric cancer through modulating NGF expression.

Authors:  Ning Dou; Dong Yang; Shijun Yu; Binghao Wu; Yong Gao; Yandong Li
Journal:  Cell Prolif       Date:  2018-07-24       Impact factor: 6.831

5.  Delta/notch-like epidermal growth factor-related receptor (DNER) orchestrates stemness and cancer progression in prostate cancer.

Authors:  Lijun Wang; Qi Wu; Shan Zhu; Zhiyu Li; Jingping Yuan; Dehua Yu; Zhiliang Xu; Juanjuan Li; Shengrong Sun; Changhua Wang
Journal:  Am J Transl Res       Date:  2017-11-15       Impact factor: 4.060

6.  Liver Stiffness Assessed by Shear Wave Elastography Predicts Postoperative Liver Failure in Patients with Hepatocellular Carcinoma.

Authors:  Yinghao Shen; Chenhao Zhou; Guodong Zhu; Guoming Shi; Xiaodong Zhu; Cheng Huang; Jian Zhou; Jia Fan; Hong Ding; Ning Ren; Hui-Chuan Sun
Journal:  J Gastrointest Surg       Date:  2017-05-16       Impact factor: 3.452

7.  A retrospective analysis of plasma concentration monitoring of fluorouracil in patients with advanced colorectal cancer.

Authors:  Quanliang Yang; Yanzhi Bi; Xiaoqian Li; Qian Liu; Jian Ma; Chengliang Zhang; Jinlin Zhang; Guangzhao He
Journal:  Eur J Hosp Pharm       Date:  2019-03-16

8.  YKL-40 promotes the migration and invasion of prostate cancer cells by regulating epithelial mesenchymal transition.

Authors:  Hailong Hao; Lei Wang; Huiqing Chen; Liwu Xie; Tao Bai; Hongyu Liu; Dongwen Wang
Journal:  Am J Transl Res       Date:  2017-08-15       Impact factor: 4.060

9.  TIM-1 attenuates the protection of ischemic preconditioning for ischemia reperfusion injury in liver transplantation.

Authors:  Yu Zhang; Yuanxing Liu; Hui Chen; Xiaoxiao Zheng; Shangzhi Xie; Wei Chen; Haofeng Ji; Shusen Zheng
Journal:  Am J Transl Res       Date:  2017-08-15       Impact factor: 4.060

10.  Evaluation of Pan-SSTRs Targeted Radioligand [64Cu]NOTA-PA1 Using Micro-PET Imaging in Xenografted Mice.

Authors:  Fei Liu; Xiaoyi Guo; Teli Liu; Xiaoxia Xu; Nan Li; Chiyi Xiong; Chun Li; Hua Zhu; Zhi Yang
Journal:  ACS Med Chem Lett       Date:  2020-02-12       Impact factor: 4.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.